TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07158242: A Phase III Randomized Double-Blind Multi-Center Treat-Through Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Children Aged 2 - 17 Years Wi

Sponsor: Hoffmann-La Roche · Phase: PHASE3 · Area: IMMUNOLOGY · Target Enrollment: 100 pts

Competing Trials Overlap

7 Active Trials

Excess Burn Exposure

$587,880

Rescue Site Savings

+$391,920

Unlock Full NCT07158242 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07158242 Rescue Dossier →